Risk Mitigation of Immunogenicity: A Key to Personalized Retinal Gene Therapy

Gene therapy (GT) for ocular disorders has advanced the most among adeno-associated virus (AAV)-mediated therapies, with one product already approved in the market. The bank of retinal gene mutations carefully compiled over 30 years, the small retinal surface that does not require high clinical vect...

Descripción completa

Detalles Bibliográficos
Autores principales: Varin, Juliette, Morival, Clément, Maillard, Noémien, Adjali, Oumeya, Cronin, Therese
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658027/
https://www.ncbi.nlm.nih.gov/pubmed/34884622
http://dx.doi.org/10.3390/ijms222312818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658027/
https://www.ncbi.nlm.nih.gov/pubmed/34884622
http://dx.doi.org/10.3390/ijms222312818

Ejemplares similares